EULAV Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

EULAV Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-45,000	Closed	-$6.42M	–	307
2019 Q2	$6.42M	Sell	45,000 -11,000	-20%	-$1.48M	0.24%	111
2019 Q1	$8.01M	Buy	56,000 +20,000	+56%	+$2.61M	0.33%	89
2018 Q4	$4.46M	Sell	36,000 -12,000	-25%	-$1.78M	0.22%	122
2018 Q3	$8.07M	Sell	48,000 -1,000	-2%	-$172K	0.35%	88
2018 Q2	$8.44M	Sell	49,000 -8,000	-14%	-$1.31M	0.39%	86
2018 Q1	$8.61M	Sell	57,000 -12,000	-17%	-$1.76M	0.41%	81
2017 Q4	$9.29M	Sell	69,000 -27,000	-28%	-$3.74M	0.44%	74
2017 Q3	$14M	Sell	96,000 -4,000	-4%	-$605K	0.66%	41
2017 Q2	$15.6M	Sell	100,000 -9,000	-8%	-$1.38M	0.76%	35
2017 Q1	$15.8M	Buy	109,000 +46,000	+73%	+$5.99M	0.81%	35
2016 Q4	$6.87M	Buy	+63,000	New	+$7.02M	0.37%	91

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

EULAV Asset Management's JAZZ Position: Q3 2019 in Review

EULAV Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2019, closing a stake of 45,000 shares — an estimated $6.42M sold.

EULAV Asset Management first reported a position in JAZZ in Q4 2016 and held it in 11 quarters. The position peaked at $15.8M in Q1 2017. 406 funds tracked by Wall St. Rank hold JAZZ as of Q3 2019.

EULAV Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
EULAV Asset Management sold 45,000 Jazz Pharmaceuticals shares in Q3 2019, an estimated $6.42M.
EULAV Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 11 quarters.
EULAV Asset Management's Jazz Pharmaceuticals position peaked at $15.8M in Q1 2017.
406 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2019.

Based on EULAV Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.